新型利福霉素对耐利福平结核分枝杆菌和MAIS复合群分枝杆菌的体外活性。

In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.

作者信息

Dickinson J M, Mitchison D A

机构信息

Department of Bacteriology, Royal Postgraduate Medical School, London.

出版信息

Tubercle. 1987 Sep;68(3):177-82. doi: 10.1016/0041-3879(87)90053-5.

DOI:10.1016/0041-3879(87)90053-5

PMID:2834842

Abstract

Comparisons were made of the in vitro activity of rifampicin, and the rifamycin derivatives, rifapentine, rifabutin, CGP 29861, CGP 7040 and CGP 27557, against rifampicin-sensitive and rifampicin-resistant strains of Mycobacterium tuberculosis and against the Mycobacterium avium/intracellulare/scrofulaceum (MAIS) complex. The new rifamycins had MICs four to eight times lower than those of rifampicin against sensitive M. tuberculosis strains. Of the 35 rifampicin-resistant strains of M. tuberculosis, 31% were sensitive to rifabutin but only 3-11% to the other rifamycins. The proportions of the MAIS strains found to be sensitive were 35% for rifampicin, 50-60% for CGP 27557, rifapentine and rifabutin and 85-92% for CGP 29861 and CGP 7040.

摘要

对利福平、利福霉素衍生物利福喷汀、利福布汀、CGP 29861、CGP 7040和CGP 27557针对结核分枝杆菌的利福平敏感和耐药菌株以及鸟分枝杆菌/胞内分枝杆菌/瘰疬分枝杆菌（MAIS）复合体的体外活性进行了比较。这些新型利福霉素对敏感结核分枝杆菌菌株的最低抑菌浓度比利福平低4至8倍。在35株利福平耐药结核分枝杆菌菌株中，31%对利福布汀敏感，但对其他利福霉素敏感的仅为3%-11%。发现对利福平敏感的MAIS菌株比例为35%，对CGP 27557、利福喷汀和利福布汀敏感的比例为50%-60%，对CGP 29861和CGP 7040敏感的比例为85%-92%。